Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Preoperative N1539 in Colorectal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntarily provide written informed consent.~* Be planned to undergo primary (no repeat procedures) open or laparoscopic colorectal surgery (laparoscopic expected to require a ≥ 5 cm incision) with bowel resection and/or anastomosis.~* ASA physical status category 1, 2, or 3.~* Female subjects not pregnant or planning/attempting to become pregnant, not lactating; or commits to the use of an acceptable form of birth control for the duration of the study.~* Have a body mass index \<40 kg/m\^2~Exclusion Criteria:~* Have a known allergy or hypersensitivity to any study treatment.~* Planned surgical procedure includes a resection beyond the peritoneal reflection, is related to an acute bout of diverticulitis, or is associated with an emergency procedure.~* Have a history of myocardial infarction within the preceding 12 months.~* Have, as determined by the investigator or the sponsor's medical monitor, a history or clinical manifestations of significant condition that would preclude participation.~* Have active or recent (within 6 months) gastrointestinal ulceration or bleeding, with exception of events related to an ulcerative colitis diagnosis.~* Have a known bleeding disorder which may be worsened with the administration of an NSAID.~* Be currently receiving treatment with oral meloxicam (Mobic®) or another NSAID within 48 hours prior to surgery.~* Have previously received N1539/IV meloxicam or received any investigational product within 30 days before dosing with study medication.~* Have undergone or be expected to undergo radiation therapy, chemotherapy, or other biological therapy for cancer treatment, within 60 days prior to screening through last follow-up.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- N1539 30 mg (Type: EXPERIMENTAL): N1539 (meloxicam injection for IV use) 30 mg every 24 hours
- IV Placebo (Type: PLACEBO_COMPARATOR): IV Placebo every 24 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).